World's Best Scientists 2026 revealed!
Prashanthi Vemuri

Prashanthi Vemuri

D-Index & Metrics

Neuroscience

D-Index
107
Citations
45306
World Ranking
609
National Ranking
345

Medicine

D-Index
107
Citations
45334
World Ranking
6212
National Ranking
3313

Overview

Prashanthi Vemuri is affiliated with the Mayo Clinic in the United States and has made significant contributions in the field of medicine, focusing primarily on dementia and cognitive impairment research. Their work spans multiple subfields, including psychiatry and mental health, radiology, nuclear medicine and imaging, physiology, neurology, and cognitive neuroscience.

The researcher's recent publications include several influential papers such as "Neuroimaging standards for research into small vessel disease-advances since 2013" (2023, The Lancet Neurology), "Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease" (2020, Nature Communications), "Performance of plasma phosphorylated tau 181 and 217 in the community" (2022, Nature Medicine), "Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease" (2020, Nature Communications), and "Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease" (2021, JAMA Neurology).

Vemuri's research addresses topics including dementia and cognitive impairment, Alzheimer's disease research and treatments, advanced neuroimaging techniques and applications, functional brain connectivity studies, advanced MRI techniques and applications, cerebrovascular and carotid artery diseases, as well as neurological disease mechanisms and treatments.

Frequent coauthors collaborating with Vemuri include:

  • Clifford R. Jack
  • Ronald C. Petersen
  • David S. Knopman
  • Jonathan Graff-Radford
  • Michelle M. Mielke

Vemuri's work is published in prominent venues with the highest number of papers appearing in Alzheimer's & Dementia, followed by Neurology, Nature Communications, JAMA Neurology, and Scientific Reports.

  • Alzheimer's & Dementia
  • Neurology
  • Nature Communications
  • JAMA Neurology
  • Scientific Reports

The extensive publication record, contributing 726 documents primarily within medicine, highlights a career dedicated to advancing understanding through neuroimaging and biomarker research. The focus on phosphorylated tau proteins and neurodegeneration is particularly reflected through multiple studies published between 2020 and 2023, which are often cited by peers.

Best Publications

  • Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

    Clifford R Jack;David S Knopman;William J Jagust;Ronald C Petersen

  • Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance

    Yaakov Stern;Eider M. Arenaza-Urquijo;David Bartrés-Faz;Sylvie Belleville

  • Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis

    Y. Iturria-Medina;R. C. Sotero;P. J. Toussaint;J. M. Mateos-Pérez

  • Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences

    Michelle M Mielke;Prashanthi Vemuri;Walter A Rocca

  • Defining imaging biomarker cut points for brain aging and Alzheimer's disease

    Clifford R. Jack;Heather J. Wiste;Stephen D. Weigand;Terry M. Therneau

  • Neuroimaging standards for research into small vessel disease—advances since 2013

    Unknown

  • An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease

    Clifford R. Jack;David S. Knopman;Stephen D. Weigand;Heather J. Wiste

  • Four distinct trajectories of tau deposition identified in Alzheimer’s disease

    Jacob W Vogel;Alexandra L Young;Neil P Oxtoby;Ruben Smith

  • Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography.

    Michelle M. Mielke;Clinton E. Hagen;Jing Xu;Xiyun Chai

  • Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease

    Clifford R. Jack;Heather J. Wiste;Prashanthi Vemuri;Stephen D. Weigand

  • Cascading network failure across the Alzheimer's disease spectrum.

    David T. Jones;David S. Knopman;Jeffrey L. Gunter;Jonathan Graff-Radford

  • Performance of plasma phosphorylated tau 181 and 217 in the community

    Unknown

  • Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies

    Prashanthi Vemuri;Jeffrey L. Gunter;Matthew L. Senjem;Jennifer L. Whitwell

  • Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease

    Jacob W. Vogel;Yasser Iturria-Medina;Olof T. Strandberg;Ruben Smith

  • MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.

    P. Vemuri;H. J. Wiste;S. D. Weigand;L. M. Shaw

  • Non-Stationarity in the ``Resting Brain's'' Modular Architecture

    David T. Jones;Prashanthi Vemuri;Matthew C. Murphy;Jeffrey L. Gunter

  • MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study.

    J. L. Whitwell;K. A. Josephs;M. E. Murray;K. Kantarci

  • Longitudinal tau PET in ageing and Alzheimer's disease.

    Clifford R Jack;Heather J Wiste;Christopher G Schwarz;Val J Lowe

  • Brain β-amyloid load approaches a plateau

    Clifford R. Jack;Heather J. Wiste;Timothy G. Lesnick;Stephen D. Weigand

  • White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities

    Jessica Alber;Suvarna Alladi;Hee Joon Bae;David A. Barton

  • Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72

    Bradley F. Boeve;Kevin B. Boylan;Neill R. Graff-Radford;Mariely DeJesus-Hernandez

  • Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span

    Clifford R. Jack;Heather J. Wiste;Stephen D. Weigand;David S. Knopman

  • Age-related changes in the default mode network are more advanced in Alzheimer disease

    D.T. Jones;M.M. Machulda;P. Vemuri;E.M. McDade

  • Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study

    Clifford R Jack;Heather J Wiste;Stephen D Weigand;Walter A Rocca

Frequent Co-Authors

Clifford R. Jack
Clifford R. Jack Mayo Clinic
Ronald C. Petersen
Ronald C. Petersen University of Pennsylvania
David S. Knopman
David S. Knopman Mayo Clinic
Val J. Lowe
Val J. Lowe Mayo Clinic
Kejal Kantarci
Kejal Kantarci Mayo Clinic
Mary M. Machulda
Mary M. Machulda Mayo Clinic
Bradley F. Boeve
Bradley F. Boeve Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Prashanthi Vemuri

Trending Scientists